World News

Through its dedicated pavilion, BIRAC is connecting visitors, investors and industry leaders with emerging Indian innovators while highlighting how its funding, infrastructure and mentorship programmes help turn scientific research into market-ready products.

The latest approval expands the clinical use of ivonescimab in China and follows previous NMPA authorisations for regimens containing the molecule.

The FDA approval was supported by findings from the Phase 3a ONWARDS clinical program, which evaluated once-weekly Awiqli® in adults with type 2 diabetes.

The transaction will be completed through a share purchase agreement with SEVER Life Sciences, under which Alfasigma will acquire 100% of Nordic Group and its subsidiaries.

Under the revised agreement, Exor can raise its shareholding in Philips to up to 22% of the company’s issued ordinary share capital and voting rights, compared with the previous 20% limit.

The procedures represent the first clinical use of the Aliya EX System since it received U.S. Food and Drug Administration (FDA) 510(k) clearance in May 2026.

Through the expanded partnership, Mayo Clinic will clinically integrate Exer AI’s hand and wrist module into its orthopaedic workflows to support musculoskeletal care.

The investment forms part of BMS’ broader US$ 40 billion commitment to strengthening its US operations, including its manufacturing and research and development (R&D) capabilities.

As part of the transaction, Actio Biosciences will establish a new privately held company dedicated to developing treatments for genetic rare neurological diseases.

The AI-powered guidance will focus on building sustainable habits related to diet, physical activity, recovery and sleep, helping individuals make informed lifestyle decisions in real time.